

Timothy Y Y Lai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6143733/publications.pdf>

Version: 2024-02-01

253
papers

14,592
citations

20759

60
h-index

24915

109
g-index

262
all docs

262
docs citations

262
times ranked

8111
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016) Tj ETQq1 1 0.784314 rgBT /Overlock 101	2.5	839
2	Revised Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy. Ophthalmology, 2011, 118, 415-422.	2.5	567
3	EVEREST STUDY. Retina, 2012, 32, 1453-1464.	1.0	523
4	Pachychoroid disease. Eye, 2019, 33, 14-33.	1.1	443
5	Updates of pathologic myopia. Progress in Retinal and Eye Research, 2016, 52, 156-187.	7.3	380
6	Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. British Journal of Ophthalmology, 2003, 87, 1453-1458.	2.1	371
7	Aqueous Humor Levels of Vascular Endothelial Growth Factor and Pigment Epithelium-Derived Factor in Polypoidal Choroidal Vasculopathy and Choroidal Neovascularization. American Journal of Ophthalmology, 2006, 141, 456-462.	1.7	347
8	Half-Dose Verteporfin Photodynamic Therapy for Acute Central Serous Chorioretinopathy. Ophthalmology, 2008, 115, 1756-1765.	2.5	291
9	Polypoidal Choroidal Vasculopathy. Ophthalmology, 2018, 125, 708-724.	2.5	282
10	Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. Ophthalmology, 2004, 111, 1576-1584.	2.5	278
11	Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Progress in Retinal and Eye Research, 2019, 73, 100770.	7.3	276
12	Myopic Choroidal Neovascularization. Ophthalmology, 2017, 124, 1690-1711.	2.5	263
13	Polypoidal Choroidal Vasculopathy. Ophthalmology, 2021, 128, 443-452.	2.5	261
14	Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. JAMA Ophthalmology, 2017, 135, 1206.	1.4	241
15	POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2013, 33, 686-716.	1.0	239
16	SAFETY ENHANCED PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2008, 28, 85-93.	1.0	221
17	Choroidal neovascularization in pathological myopia. Progress in Retinal and Eye Research, 2012, 31, 495-525.	7.3	218
18	Indocyanine green staining and removal of internal limiting membrane in macular hole surgery: histology and outcome. American Journal of Ophthalmology, 2001, 132, 178-183.	1.7	192

#	ARTICLE	IF	CITATIONS
19	Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. <i>Lancet, The</i> , 2022, 399, 729-740.	6.3	190
20	Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. <i>British Journal of Ophthalmology</i> , 2006, 90, 869-874.	2.1	175
21	Epiretinal membrane surgery with or without internal limiting membrane peeling. <i>Clinical and Experimental Ophthalmology</i> , 2005, 33, 379-385.	1.3	162
22	Intravitreal Bevacizumab (Avastin) for Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy, Secondary to Punctate Inner Choroidopathy, or of Idiopathic Origin. <i>American Journal of Ophthalmology</i> , 2007, 143, 977-983.e1.	1.7	159
23	The REVEAL Study. <i>Ophthalmology</i> , 2015, 122, 1402-1415.	2.5	149
24	Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. <i>British Journal of Ophthalmology</i> , 2008, 92, 661-666.	2.1	148
25	New loci and coding variants confer risk for age-related macular degeneration in East Asians. <i>Nature Communications</i> , 2015, 6, 6063.	5.8	147
26	Polypoidal choroidal vasculopathy in Chinese patients. <i>British Journal of Ophthalmology</i> , 2002, 86, 892-897.	2.1	143
27	IMI Pathologic Myopia. , 2021, 62, 5.		140
28	Myopic choroidal neovascularisation: current concepts and update on clinical management. <i>British Journal of Ophthalmology</i> , 2015, 99, 289-296.	2.1	135
29	Intravitreal Bevacizumab (Avastin) for Myopic Choroidal Neovascularization. <i>Ophthalmology</i> , 2007, 114, 2190-2196.e2.	2.5	127
30	Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. <i>Progress in Retinal and Eye Research</i> , 2018, 63, 92-106.	7.3	125
31	Effect of Indocyanine Green and Illumination on Gene Expression in Human Retinal Pigment Epithelial Cells. , 2003, 44, 370.		113
32	Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. <i>American Journal of Ophthalmology</i> , 2004, 137, 826-833.	1.7	113
33	Intravitreal Triamcinolone plus Sequential Grid Laser versus Triamcinolone or Laser Alone for Treating Diabetic Macular Edema. <i>Ophthalmology</i> , 2007, 114, 2162-2167.e1.	2.5	109
34	Indocyanine green assisted retinal internal limiting membrane removal in stage 3 or 4 macular hole surgery. <i>British Journal of Ophthalmology</i> , 2003, 87, 71-74.	2.1	107
35	Multifocal Electroretinographic Changes in Patients Receiving Hydroxychloroquine Therapy. <i>American Journal of Ophthalmology</i> , 2005, 140, 794-807.e1.	1.7	104
36	EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE. <i>Retina</i> , 2018, 38, 1464-1477.	1.0	99

#	ARTICLE	IF	CITATIONS
37	Indocyanine green-assisted internal limiting membrane removal in epiretinal membrane surgery: A clinical and histologic study. <i>American Journal of Ophthalmology</i> , 2004, 138, 194-199.	1.7	95
38	Vitreotomy and gas tamponade without internal limiting membrane peeling for myopic foveoschisis. <i>British Journal of Ophthalmology</i> , 2005, 89, 1180-1183.	2.1	94
39	Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. <i>British Journal of Ophthalmology</i> , 2009, 93, 150-154.	2.1	93
40	Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. <i>JAMA Ophthalmology</i> , 2020, 138, 935.	1.4	93
41	Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. <i>Eye</i> , 2012, 26, 1004-1011.	1.1	92
42	INTRAVITREAL RANIBIZUMAB FOR THE PRIMARY TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA. <i>Retina</i> , 2009, 29, 750-756.	1.0	91
43	IMPROVEMENT IN MULTIFOCAL ELECTRORETINOGRAPHY AFTER HALF-DOSE VERTEPORFIN PHOTODYNAMIC THERAPY FOR CENTRAL SEROUS CHORIORETINOPATHY. <i>Retina</i> , 2011, 31, 1378-1386.	1.0	90
44	Choroidal neovascularisation in pathological myopia: an update in management. <i>British Journal of Ophthalmology</i> , 2005, 89, 1522-1528.	2.1	86
45	Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. <i>Eye</i> , 2009, 23, 543-548.	1.1	85
46	The Clinical Applications of Multifocal Electroretinography: A Systematic Review. <i>Survey of Ophthalmology</i> , 2007, 52, 61-96.	1.7	83
47	EFFICACY OF 1.25 MG VERSUS 2.5 MG INTRAVITREAL BEVACIZUMAB FOR DIABETIC MACULAR EDEMA. <i>Retina</i> , 2009, 29, 292-299.	1.0	81
48	PRIMARY 23-GAUGE TRANSCONJUNCTIVAL SUTURELESS VITRECTOMY FOR RHEGMATOGENOUS RETINAL DETACHMENT. <i>Retina</i> , 2008, 28, 1075-1081.	1.0	79
49	INTRAVITREAL RANIBIZUMAB WITH OR WITHOUT PHOTODYNAMIC THERAPY FOR THE TREATMENT OF SYMPTOMATIC POLYPOIDAL CHOROIDAL VASCULOPATHY. <i>Retina</i> , 2011, 31, 1581-1588.	1.0	79
50	Epiretinal membrane formation with internal limiting membrane wrinkling after Nd:YAG laser membranotomy in valsalva retinopathy. <i>American Journal of Ophthalmology</i> , 2003, 136, 763-766.	1.7	77
51	CHANGES IN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AND PIGMENT EPITHELIAL-DERIVED FACTOR LEVELS FOLLOWING INTRAVITREAL BEVACIZUMAB INJECTIONS FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION OR PATHOLOGIC MYOPIA. <i>Retina</i> , 2008, 28, 1308-1313.	1.0	77
52	Risk Factors for Recurrence of Serous Macular Detachment in Untreated Patients with Central Serous Chorioretinopathy. <i>Ophthalmic Research</i> , 2011, 46, 160-163.	1.0	77
53	Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization. <i>American Journal of Ophthalmology</i> , 2008, 146, 410-416.e1.	1.7	76
54	Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin. <i>American Journal of Ophthalmology</i> , 2003, 136, 836-845.	1.7	74

#	ARTICLE	IF	CITATIONS
55	Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. <i>British Journal of Ophthalmology</i> , 2006, 90, 337-341.	2.1	72
56	Advances of optical coherence tomography in myopia and pathologic myopia. <i>Eye</i> , 2016, 30, 901-916.	1.1	70
57	A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2007, 91, 199-203.	2.1	69
58	A missense variant in FGD6 confers increased risk of polypoidal choroidal vasculopathy. <i>Nature Genetics</i> , 2016, 48, 640-647.	9.4	68
59	Peripheral and posterior pole retinal lesions in association with high myopia: a cross-sectional community-based study in Hong Kong. <i>Eye</i> , 2008, 22, 209-213.	1.1	66
60	Pediatric Ocular Surface Infections: A 5-year Review of Demographics, Clinical Features, Risk Factors, Microbiological Results, and Treatment. <i>Cornea</i> , 2011, 30, 995-1002.	0.9	65
61	Internal limiting membrane staining with various concentrations of indocyanine green dye under air in macular surgeries. <i>American Journal of Ophthalmology</i> , 2003, 136, 223-230.	1.7	63
62	Effects of trypan blue on cell viability and gene expression in human retinal pigment epithelial cells. <i>British Journal of Ophthalmology</i> , 2004, 88, 1590-1594.	2.1	63
63	Genotype-Phenotype Analysis of Bietti's Crystalline Dystrophy in Patients with CYP4V2 Mutations. , 2007, 48, 5212.		63
64	Targeted Sequencing of 179 Genes Associated with Hereditary Retinal Dystrophies and 10 Candidate Genes Identifies Novel and Known Mutations in Patients with Various Retinal Diseases. , 2013, 54, 2186.		63
65	The potential of spectral domain optical coherence tomography imaging based retinal biomarkers. <i>International Journal of Retina and Vitreous</i> , 2017, 3, 1.	0.9	61
66	Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization. <i>Ophthalmology</i> , 2003, 110, 2395-2402.	2.5	60
67	Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: a 6-month prospective pilot study. <i>Eye</i> , 2005, 19, 885-890.	1.1	60
68	PRESENCE OF CRYSTALLINE LENS AS A PROTECTIVE FACTOR FOR THE LATE DEVELOPMENT OF OPEN ANGLE GLAUCOMA AFTER VITRECTOMY. <i>Retina</i> , 2009, 29, 218-224.	1.0	57
69	Genes in the High-Density Lipoprotein Metabolic Pathway in Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy. <i>Ophthalmology</i> , 2014, 121, 911-916.	2.5	56
70	Internal limiting membrane removal in macular hole surgery for severely myopic eyes: a case-control study. <i>British Journal of Ophthalmology</i> , 2003, 87, 885-889.	2.1	55
71	Penetrating keratoplasty in children: visual and graft outcome. <i>British Journal of Ophthalmology</i> , 2003, 87, 1212-1214.	2.1	54
72	Visual Field and Multifocal Electroretinography and their Correlations in Patients on Hydroxychloroquine Therapy. <i>Documenta Ophthalmologica</i> , 2006, 112, 177-187.	1.0	54

#	ARTICLE	IF	CITATIONS
73	Compound Heterozygosity of Two Novel Truncation Mutations in <i>RP1</i> Causing Autosomal Recessive Retinitis Pigmentosa. , 2010, 51, 2236.		54
74	Quality of Reporting of Key Methodological Items of Randomized Controlled Trials in Clinical Ophthalmic Journals. <i>Ophthalmic Epidemiology</i> , 2007, 14, 390-398.	0.8	53
75	The natural history of polypoidal choroidal vasculopathy: a multi-center series of untreated Asian patients. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2015, 253, 2075-2085.	1.0	53
76	Macular hole surgery with or without indocyanine green stained internal limiting membrane peeling. <i>Clinical and Experimental Ophthalmology</i> , 2003, 31, 470-475.	1.3	51
77	Results of high-density silicone oil as a tamponade agent in macular hole retinal detachment in patients with high myopia. <i>British Journal of Ophthalmology</i> , 2007, 91, 719-721.	2.1	50
78	Polypoidal choroidal vasculopathy: an update on therapeutic approaches. <i>Journal of Ophthalmic and Vision Research</i> , 2013, 8, 359-71.	0.7	50
79	Review of Clinical Features, Microbiological Spectrum, and Treatment Outcomes of Endogenous Endophthalmitis over an 8-Year Period. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-5.	0.6	49
80	Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. <i>British Journal of Ophthalmology</i> , 2007, 91, 174-179.	2.1	48
81	Retinal ganglion cells toxicity caused by photosensitising effects of intravitreal indocyanine green with illumination in rat eyes. <i>British Journal of Ophthalmology</i> , 2006, 90, 99-102.	2.1	47
82	COMBINED PHOTODYNAMIC THERAPY AND INTRAVITREAL TRIAMCINOLONE FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO PUNCTATE INNER CHOROIDOPATHY OR OF IDIOPATHIC ORIGIN. <i>Retina</i> , 2008, 28, 71-80.	1.0	45
83	THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES. <i>Retina</i> , 2021, 41, 1-19.	1.0	44
84	Differentiation of Exudative Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in the <i>ARMS2</i> / <i>HTRA1</i> Locus. , 2012, 53, 3175.		43
85	Trypan blue- and indocyanine green-assisted epiretinal membrane surgery: clinical and histopathological studies. <i>Eye</i> , 2004, 18, 882-888.	1.1	42
86	Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 1877-1880.	1.0	42
87	Alterations in Serum Fatty Acid Concentrations and Desaturase Activities in Bietti Crystalline Dystrophy Unaffected by <i>CYP4V2</i> Genotypes. , 2010, 51, 1092.		42
88	Photoreceptor inner segment ellipsoid band integrity on spectral domain optical coherence tomography. <i>Clinical Ophthalmology</i> , 2014, 8, 2507.	0.9	42
89	Surgical treatment for diabetic vitreoretinal diseases: a review. <i>Clinical and Experimental Ophthalmology</i> , 2016, 44, 340-354.	1.3	42
90	Ophthalmic manifestations and risk factors for mortality of HIV patients in the post-highly active anti-retroviral therapy era. <i>Clinical and Experimental Ophthalmology</i> , 2011, 39, 99-104.	1.3	41

#	ARTICLE	IF	CITATIONS
91	Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization. Canadian Journal of Ophthalmology, 2012, 47, 269-274.	0.4	41
92	Neuroprotective effect of epigallocatechin-3-gallate in a mouse model of chronic glaucoma. Neuroscience Letters, 2015, 600, 132-136.	1.0	41
93	Intravitreal Injectionâ€™Technique and Safety. Asia-Pacific Journal of Ophthalmology, 2015, 4, 321-328.	1.3	40
94	Pachychoroid: current concepts on clinical features and pathogenesis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1385-1400.	1.0	40
95	Photodynamic Therapy in Macular Diseases of Asian Populations: When East Meets West. Japanese Journal of Ophthalmology, 2006, 50, 161-169.	0.9	39
96	THE ROLES OF GENETIC FACTORS IN UVEITIS AND THEIR CLINICAL SIGNIFICANCE. Retina, 2014, 34, 1-11.	1.0	39
97	Associations of the C2-CFB-RDBP-SKIV2L Locus with Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Ophthalmology, 2013, 120, 837-843.	2.5	38
98	MYOPIC CHOROIDAL NEOVASCULARIZATION. Retina, 2016, 36, 1614-1621.	1.0	37
99	Choroidal structures in polypoidal choroidal vasculopathy, neovascular age-related maculopathy, and healthy eyes determined by binarization of swept source optical coherence tomographic images. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 935-943.	1.0	37
100	Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation. Scientific Reports, 2017, 7, 45081.	1.6	37
101	Pars plana vitrectomy in the management of retained intravitreal lens fragments after cataract surgery. Clinical and Experimental Ophthalmology, 2002, 30, 399-403.	1.3	36
102	How Evidence-Based Are Publications in Clinical Ophthalmic Journals?. , 2006, 47, 1831.		35
103	NOVEL AND HOMOZYGOUS BEST1 MUTATIONS IN CHINESE PATIENTS WITH BEST VITELLIFORM MACULAR DYSTROPHY. Retina, 2010, 30, 820-827.	1.0	34
104	Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clinical Interventions in Aging, 2013, 8, 467.	1.3	34
105	UNDERSTANDING INDOCYANINE GREEN ANGIOGRAPHY IN POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2014, 34, 2397-2406.	1.0	34
106	Genetics of Bietti Crystalline Dystrophy. Asia-Pacific Journal of Ophthalmology, 2016, 5, 245-252.	1.3	34
107	Retinal pigment epithelial tear following intravitreal ranibizumab injections for neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1225-1227.	1.0	33
108	Immediate pars plana vitrectomy for dislocated intravitreal lens fragments during cataract surgery. Eye, 2005, 19, 1157-1162.	1.1	32

#	ARTICLE	IF	CITATIONS
109	Influence of molecular genetics in Vogt-Koyanagi-Harada disease. <i>Journal of Ophthalmic Inflammation and Infection</i> , 2014, 4, 20.	1.2	32
110	LONG-TERM OUTCOMES OF RANIBIZUMAB TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION IN EAST-ASIAN PATIENTS FROM THE RADIANCE STUDY. <i>Retina</i> , 2018, 38, 2228-2238.	1.0	32
111	Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular oedema. <i>British Journal of Ophthalmology</i> , 2006, 90, 1137-1141.	2.1	31
112	Assessment of macular function by multifocal electroretinography following epiretinal membrane surgery with indocyanine green-assisted internal limiting membrane peeling. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2006, 245, 148-154.	1.0	30
113	Anti-VEGF Therapy for Neovascular AMD and Polypoidal Choroidal Vasculopathy. <i>Asia-Pacific Journal of Ophthalmology</i> , 2017, 6, 527-534.	1.3	29
114	Identification of <i>ANGPT2</i> as a New Gene for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in the Chinese and Japanese Populations. , 2017, 58, 1076.		29
115	Correlation between functional and anatomical assessments by multifocal electroretinography and optical coherence tomography in central serous chorioretinopathy. <i>Documenta Ophthalmologica</i> , 2010, 120, 193-200.	1.0	28
116	Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19. <i>Asia-Pacific Journal of Ophthalmology</i> , 2020, 9, 85-87.	1.3	28
117	Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by sequential gas displacement and photodynamic therapy: a pilot study of one-year follow up. <i>Clinical and Experimental Ophthalmology</i> , 2005, 33, 611-618.	1.3	27
118	Black diaphragm aniridia intraocular lens for aniridia and albinism. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2005, 243, 501-504.	1.0	27
119	Association of <i>C2</i> and <i>CFB</i> Polymorphisms with Anterior Uveitis. , 2012, 53, 4969.		27
120	Gender specific association of a complement component 3 polymorphism with polypoidal choroidal vasculopathy. <i>Scientific Reports</i> , 2014, 4, 7018.	1.6	27
121	Ethnic differences in the association of <i>SERPING1</i> with age-related macular degeneration and polypoidal choroidal vasculopathy. <i>Scientific Reports</i> , 2015, 5, 9424.	1.6	27
122	The effects of indocyanine green and endoillumination on rabbit retina: an electroretinographic and histological study. <i>British Journal of Ophthalmology</i> , 2005, 89, 897-900.	2.1	26
123	Long-term results of oral valganciclovir for treatment of anterior segment inflammation secondary to cytomegalovirus infection. <i>Clinical Ophthalmology</i> , 2012, 6, 595.	0.9	26
124	RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION. <i>Retina</i> , 2019, 39, 1985-1994.	1.0	26
125	First and second-order kernel multifocal electroretinography abnormalities in acute central serous chorioretinopathy. <i>Documenta Ophthalmologica</i> , 2008, 116, 29-40.	1.0	25
126	Photodynamic Therapy With or Without Intravitreal Triamcinolone Acetonide for Symptomatic Polypoidal Choroidal Vasculopathy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2010, 26, 91-96.	0.6	25

#	ARTICLE	IF	CITATIONS
127	Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes. <i>Ophthalmology</i> , 2018, 125, 850-862.	2.5	25
128	Is ophthalmology evidence based? A clinical audit of the emergency unit of a regional eye hospital. <i>British Journal of Ophthalmology</i> , 2003, 87, 385-390.	2.1	24
129	Multifocal electroretinogram demonstrated macular toxicity associated with ethambutol related optic neuropathy. <i>British Journal of Ophthalmology</i> , 2005, 89, 774-775.	2.1	24
130	VISUAL OUTCOMES AND GROWTH FACTOR CHANGES OF TWO DOSAGES OF INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 1218-1226.	1.0	24
131	FPR1 interacts with CFH, HTRA1 and smoking in exudative age-related macular degeneration and polypoidal choroidal vasculopathy. <i>Eye</i> , 2014, 28, 1502-1510.	1.1	24
132	HTRA1 promoter variant differentiates polypoidal choroidal vasculopathy from exudative age-related macular degeneration. <i>Scientific Reports</i> , 2016, 6, 28639.	1.6	24
133	Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration. <i>BioMed Research International</i> , 2018, 2018, 1-10.	0.9	24
134	Spectral Domain Optical Coherence Tomography Features and Classification Systems for Diabetic Macular Edema. <i>Asia-Pacific Journal of Ophthalmology</i> , 2016, 5, 360-367.	1.3	23
135	Evolving treatment paradigms for PCV. <i>Eye</i> , 2022, 36, 257-265.	1.1	23
136	Association of Genetic Variants on 8p21 and 4q12 with Age-Related Macular Degeneration in Asian Populations. , 2012, 53, 6576.		22
137	Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization. <i>Clinical Ophthalmology</i> , 2012, 6, 1233.	0.9	22
138	A prospective study on trypan blue capsule staining under air vs under viscoelastic. <i>Eye</i> , 2006, 20, 820-825.	1.1	21
139	Focal choroidal excavation in patients with central serous chorioretinopathy. <i>Eye</i> , 2015, 29, 453-459.	1.1	21
140	Classification of Exudative Age-Related Macular Degeneration With Pachyvessels on En Face Swept-Source Optical Coherence Tomography. , 2017, 58, 1054.		21
141	Diabetic macular oedema: evidence-based treatment recommendations for Asian countries. <i>Clinical and Experimental Ophthalmology</i> , 2018, 46, 75-86.	1.3	21
142	Latest Developments in Polypoidal Choroidal Vasculopathy: Epidemiology, Etiology, Diagnosis, and Treatment. <i>Asia-Pacific Journal of Ophthalmology</i> , 2020, 9, 260-268.	1.3	21
143	CFH 184G as a genetic risk marker for anterior uveitis in Chinese females. <i>Molecular Vision</i> , 2011, 17, 2655-64.	1.1	21
144	Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Ethnicity, Age, and Ocular Characteristics in RADIANCE. <i>Ophthalmologica</i> , 2016, 236, 19-28.	1.0	20

#	ARTICLE	IF	CITATIONS
145	Non-ICGA treatment criteria for Suboptimal Anti-VEGF Response for Polypoidal Choroidal Vasculopathy: APOIS PCV Workgroup Report 2. <i>Ophthalmology Retina</i> , 2021, 5, 945-953.	1.2	20
146	Managing Uveitis during the COVID-19 Pandemic. <i>Ophthalmology</i> , 2020, 127, e65-e67.	2.5	20
147	<i>Stenotrophomonas maltophilia</i> endophthalmitis after penetrating injury by a wooden splinter. <i>Eye</i> , 2001, 15, 353-354.	1.1	19
148	Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion. <i>British Journal of Ophthalmology</i> , 2006, 90, 243-244.	2.1	19
149	Long-Term Follow-Up of Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization due to Choroidal Osteoma. <i>Case Reports in Ophthalmology</i> , 2012, 3, 200-204.	0.3	19
150	Identification of <i>PGF</i> as a New Gene for Neovascular Age-Related Macular Degeneration in a Chinese Population. , 2016, 57, 1714.		19
151	Results of Trabeculectomy With Adjunctive Intraoperative Mitomycin C in Chinese Patients With Glaucoma. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2006, 37, 33-41.	0.4	19
152	Complement factor H and interleukin gene polymorphisms in patients with non-infectious intermediate and posterior uveitis. <i>Molecular Vision</i> , 2012, 18, 1865-72.	1.1	19
153	Treat-and-Extend Regimens for the Management of Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations From the Asia-Pacific Vitreo-retina Society. <i>Asia-Pacific Journal of Ophthalmology</i> , 2021, 10, 507-518.	1.3	19
154	Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma. <i>Journal of Ophthalmology</i> , 2014, 2014, 1-8.	0.6	18
155	Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study. <i>PLoS ONE</i> , 2020, 15, e0227557.	1.1	18
156	Intravitreal Dexamethasone for Diabetic Macular Edema: A Pilot Study. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010, 41, 26-30.	0.4	18
157	Association of NR2E3 but Not NRL Mutations with Retinitis Pigmentosa in the Chinese Population. , 2010, 51, 2229.		17
158	Impact of virtual reality simulation on learning barriers of phacoemulsification perceived by residents. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 885-893.	0.9	17
159	Current management strategy of polypoidal choroidal vasculopathy. <i>Indian Journal of Ophthalmology</i> , 2018, 66, 1727.	0.5	17
160	Optical Coherence Tomography Classification Systems for Diabetic Macular Edema and Their Associations With Visual Outcome and Treatment Responses – An Updated Review. <i>Asia-Pacific Journal of Ophthalmology</i> , 2022, 11, 247-257.	1.3	17
161	Anti-vascular Endothelial Growth Factor Therapy for Myopic Choroidal Neovascularization. <i>Retina</i> , 2012, 32, 1443-1445.	1.0	16
162	Association of <i>CFH</i> and <i>SERPINC1</i> polymorphisms with anterior uveitis. <i>British Journal of Ophthalmology</i> , 2013, 97, 1475-1480.	2.1	16

#	ARTICLE	IF	CITATIONS
163	Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet's disease-related uveitis. <i>Journal of Ophthalmic Inflammation and Infection</i> , 2019, 9, 14.	1.2	16
164	Photodynamic therapy with verteporfin for vasoproliferative tumour of the retina. <i>Acta Ophthalmologica</i> , 2010, 88, 711-712.	0.6	15
165	Contribution of SNRNP200 sequence variations to retinitis pigmentosa. <i>Eye</i> , 2013, 27, 1204-1213.	1.1	15
166	OCT-based biomarkers for predicting treatment response in eyes with centre-involved diabetic macular oedema treated with anti-VEGF injections: a real-life retina clinic-based study. <i>British Journal of Ophthalmology</i> , 2023, 107, 525-533.	2.1	15
167	Ranibizumab for myopic choroidal neovascularization. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1385-1393.	1.4	14
168	Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis). <i>Transactions of the American Ophthalmological Society</i> , 2015, 113, T8.	1.4	14
169	Multifocal electroretinogram and optical coherence tomography of commotio retinae and traumatic macular hole. <i>Eye</i> , 2005, 19, 219-221.	1.1	13
170	Multifocal electroretinography in dengue fever-associated maculopathy. <i>British Journal of Ophthalmology</i> , 2007, 91, 1084-1085.	2.1	13
171	Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 208.	0.4	13
172	An Update in Laser and Pharmaceutical Treatment for Polypoidal Choroidal Vasculopathy. <i>Asia-Pacific Journal of Ophthalmology</i> , 2012, 1, 97-104.	1.3	13
173	Clinical Characteristics of Intermediate Uveitis in Chinese Patients. <i>Ocular Immunology and Inflammation</i> , 2013, 21, 71-76.	1.0	13
174	Differential pattern of RP1 mutations in retinitis pigmentosa. <i>Molecular Vision</i> , 2010, 16, 1353-60.	1.1	13
175	Laser induced chorioretinal venous anastomosis in ischaemic central retinal vein occlusion. <i>British Journal of Ophthalmology</i> , 2003, 87, 1043-1044.	2.1	12
176	Manganese Superoxide Dismutase and Chemokine Genes Polymorphisms in Chinese Patients with Anterior Uveitis. , 2009, 50, 5596.		12
177	Tyrosinase gene (<i>TYR</i>) mutations in Chinese patients with oculocutaneous albinism type 1. <i>Clinical and Experimental Ophthalmology</i> , 2010, 38, 37-42.	1.3	12
178	Association of <i>ABCG1</i> With Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Chinese and Japanese. , 2016, 57, 5758.		11
179	Fundus Autofluorescence Imaging in the Assessment of Acute Zonal Occult Outer Retinopathy. <i>Ophthalmologica</i> , 2017, 237, 153-158.	1.0	11
180	An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 963-973.	1.0	11

#	ARTICLE	IF	CITATIONS
181	Treatment of Punctate Inner Choroidopathy with Choroidal Neovascularization Using Corticosteroid and Intravitreal Ranibizumab. <i>BioMed Research International</i> , 2018, 2018, 1-7.	0.9	11
182	Multifocal electroretinography changes in patients on ethambutol therapy. <i>Eye</i> , 2009, 23, 1707-1713.	1.1	10
183	REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY. <i>Retina</i> , 2020, 40, 1529-1539.	1.0	10
184	Optical Coherence Tomography Angiography Compared with Multimodal Imaging for Diagnosing Neovascular Central Serous Chorioretinopathy. <i>American Journal of Ophthalmology</i> , 2021, 232, 70-82.	1.7	10
185	Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 43-54.	1.0	9
186	Photodynamic therapy with verteporfin in laser-induced choroidal neovascularization. <i>American Journal of Ophthalmology</i> , 2003, 136, 565-567.	1.7	8
187	Do doctors act on their self-reported intention to computerize? A follow-up population-based survey in Hong Kong. <i>International Journal of Medical Informatics</i> , 2004, 73, 415-431.	1.6	8
188	Prioritization of cataract surgery: Visual analogue scale versus scoring system. <i>ANZ Journal of Surgery</i> , 2005, 75, 587-592.	0.3	8
189	Effect of application duration of 2% lidocaine jelly on aqueous lidocaine concentration for topical anesthesia in cataract surgery. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2006, 244, 1096-1100.	1.0	8
190	COMBINED HIGH-DOSE SUB-TENON TRIAMCINOLONE, INTRAVITREAL BEVACIZUMAB, AND LASER PHOTOCOAGULATION FOR REFRACTORY DIABETIC MACULAR EDEMA. <i>Retina</i> , 2012, 32, 672-678.	1.0	8
191	Choroidal thickness in Chinese patients with non-arteritic anterior ischemic optic neuropathy. <i>BMC Ophthalmology</i> , 2016, 16, 153.	0.6	8
192	Evaluation of the association of C5 with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. <i>Eye and Vision (London, England)</i> , 2019, 6, 34.	1.4	8
193	EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB IN ASIAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2019, 39, 537-547.	1.0	8
194	RANIBIZUMAB WITH OR WITHOUT VERTEPORFIN PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. <i>Retina</i> , 2021, 41, 387-392.	1.0	8
195	Factors associated with variability in response of diabetic macular oedema after intravitreal triamcinolone. <i>Clinical and Experimental Ophthalmology</i> , 2009, 37, 602-608.	1.3	7
196	Ocular imaging at the cutting-edge. <i>Eye</i> , 2021, 35, 1-3.	1.1	7
197	Progression of diabetic retinopathy after endophthalmitis. <i>Ophthalmology</i> , 2000, 107, 619.	2.5	6
198	Physicians's™ perceptions towards the impact of and willingness to pay for clinical computerization in Hong Kong. <i>International Journal of Medical Informatics</i> , 2004, 73, 403-414.	1.6	6

#	ARTICLE	IF	CITATIONS
199	Asymmetrical Ocular Involvement and Persistent Fetal Vasculature in an Adult With Osteoporosis-Pseudoglioma Syndrome. <i>JAMA Ophthalmology</i> , 2006, 124, 422.	2.6	6
200	Safety and Efficacy of Micro-Incisional Cataract Surgery with Bimanual Phacoemulsification for White Mature Cataract. <i>Ophthalmologica</i> , 2007, 221, 24-28.	1.0	6
201	Late appearance of an intracameral ophthalmic ointment globule after uneventful phacoemulsification. <i>Japanese Journal of Ophthalmology</i> , 2009, 53, 553-555.	0.9	6
202	Changes in first- and second-order multifocal electroretinography in idiopathic macular hole and their correlations with macular hole diameter and visual acuity. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 477-484.	1.0	6
203	Application of multifocal visual evoked potentials in the assessment of visual dysfunction in macular diseases. <i>Eye</i> , 2011, 25, 1302-1309.	1.1	6
204	A Case of Dengue Maculopathy with Spontaneous Recovery. <i>Case Reports in Ophthalmology</i> , 2013, 4, 28-33.	0.3	6
205	Ophthalmic Application of Anti-VEGF Therapy. <i>Asia-Pacific Journal of Ophthalmology</i> , 2017, 6, 479-480.	1.3	6
206	Visualising the choriocapillaris: Histology, imaging modalities and clinical research – A review. <i>Clinical and Experimental Ophthalmology</i> , 2022, 50, 91-103.	1.3	6
207	Association between Retinal Thickness Variability and Visual Acuity Outcome during Maintenance Therapy Using Intravitreal Anti-Vascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration. <i>Journal of Personalized Medicine</i> , 2021, 11, 1024.	1.1	6
208	Clinically relevant factors associated with a binary outcome of diabetic macular ischaemia: an OCTA study. <i>British Journal of Ophthalmology</i> , 2023, 107, 1311-1318.	2.1	6
209	Laser photocoagulation of indocyanine green angiographically identified feeder vessels to idiopathic polypoidal choroidal vasculopathy. <i>American Journal of Ophthalmology</i> , 2004, 138, 693-694.	1.7	5
210	Spontaneous resolution of retinal pigment epithelial tears and pigment epithelial detachment following blunt trauma. <i>Eye</i> , 2007, 21, 891-893.	1.1	5
211	Development of novel drugs for ocular diseases: possibilities for individualized therapy. <i>Personalized Medicine</i> , 2010, 7, 371-386.	0.8	5
212	Anti-Vascular Endothelial Growth Factor Therapy for Myopic Choroidal Neovascularization. <i>Asia-Pacific Journal of Ophthalmology</i> , 2017, 6, 554-560.	1.3	5
213	Ophthalmic Application of Anti-VEGF Therapy. <i>Asia-Pacific Journal of Ophthalmology</i> , 2017, 6, .	1.3	5
214	Correlation of Clinical and Optical Coherence Tomography Findings in Postoperative Macular Hole Closure Status. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2003, 34, 25-32.	0.4	5
215	ILM peeling in macular hole surgery. <i>Ophthalmology</i> , 2002, 109, 822.	2.5	4
216	Acute Staphylococcus aureus wound infection after temporal clear corneal phacoemulsification. <i>Eye</i> , 2006, 20, 258-260.	1.1	4

#	ARTICLE	IF	CITATIONS
217	Panuveitis as an initial presentation of extranodal NK/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 648-650.	0.6	4
218	RANIBIZUMAB 0.5 MG TREATMENT IN ADOLESCENTS WITH CHOROIDAL NEOVASCULARIZATION: SUBGROUP ANALYSIS DATA FROM THE MINERVA STUDY. <i>Retinal Cases and Brief Reports</i> , 2021, 15, 348-355.	0.3	4
219	Pharmacotherapy for Choroidal Neovascularization Due to Uncommon Causes. <i>Current Pharmaceutical Design</i> , 2019, 24, 4882-4895.	0.9	4
220	Insights Into the Global Epidemic of High Myopia and Its Implications. <i>JAMA Ophthalmology</i> , 2022, 140, 123.	1.4	4
221	Alveolar rhabdomyosarcoma of the sphenoid sinus mimicking optic neuritis presenting with intermittent visual loss in an adult. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6333-6336.	1.0	3
222	Retinectomy for intractable glaucoma. <i>British Journal of Ophthalmology</i> , 2004, 88, 1352-1353.	2.1	2
223	What's New in Uveitis and Ocular Inflammation?. <i>Asia-Pacific Journal of Ophthalmology</i> , 2013, 2, 139-140.	1.3	2
224	Machines and Cutters: Stellaris PC. <i>Developments in Ophthalmology</i> , 2014, 54, 8-16.	0.1	2
225	Central Serous Chorioretinopathy. , 2017, , 227-251.		2
226	Identification and characterization of a novel promoter variant in placental growth factor for neovascular age-related macular degeneration. <i>Experimental Eye Research</i> , 2019, 187, 107748.	1.2	2
227	Primary Orbital Ewing Sarcoma in a Middle-aged Woman. <i>JAMA Ophthalmology</i> , 2000, 118, 592.	2.6	2
228	Sub-Tenon's injection for posterior segment surgery. <i>Ophthalmology</i> , 2001, 108, 1006-1007.	2.5	1
229	Massive subretinal haemorrhage associated with central serous chorioretinopathy. <i>Eye</i> , 2001, 15, 121-123.	1.1	1
230	Assessment of macular function by multifocal electroretinography following epiretinal membrane surgery with indocyanine green-assisted internal limited membrane peeling: reply. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 1239-1240.	1.0	1
231	IMPROVEMENT IN MULTIFOCAL ELECTRORETINOGRAPHY AFTER HALF-DOSE VERTEPORFIN PHOTODYNAMIC THERAPY FOR CENTRAL SEROUS CHORIORETINOPATHY. <i>Retina</i> , 2011, Publish Ahead of Print, .	1.0	1
232	An Update on Intravitreal Aflibercept in Treating Macular Diseases. <i>Asia-Pacific Journal of Ophthalmology</i> , 2017, 6, 225-227.	1.3	1
233	Clinical Trials Related to Myopic Choroidal Neovascularization. , 2020, , 283-295.		1
234	Recommendations of the treat-and-extend regimen for neovascular age-related macular degeneration: 2020 updates. <i>Hong Kong Journal of Ophthalmology: the Official Publication of the College of Ophthalmologists of Hong Kong = Xianggang Yan Ke Xue Kan: Xianggang Yan Ke Yi Xue Yuan</i> , 2022, 25, 39-46.	0.3	1

#	ARTICLE	IF	CITATIONS
235	Disinfection of vacuum control manifold to prevent postoperative endophthalmitis. <i>Ophthalmology</i> , 2001, 108, 636.	2.5	0
236	Acrylic intraocular lens placement in conjunction with pars plana vitrectomy. <i>American Journal of Ophthalmology</i> , 2002, 133, 586.	1.7	0
237	Iatrogenic punctate chorioretinopathy after internal limiting membrane peeling. <i>American Journal of Ophthalmology</i> , 2003, 136, 396.	1.7	0
238	Internal limiting membrane staining with various concentrations of indocyanine green dye under air in macular surgeries: Author Reply. <i>American Journal of Ophthalmology</i> , 2004, 137, 589-590.	1.7	0
239	Indocyanine green-assisted macular pucker surgery - response.. <i>Clinical and Experimental Ophthalmology</i> , 2006, 34, 96-97.	1.3	0
240	Osteoporosis-Pseudoglioma Syndrome May Not Be Caused by Persistent Fetal Vasculature—Reply. <i>JAMA Ophthalmology</i> , 2007, 125, 433.	2.6	0
241	Multifocal electroretinography: update on clinical application and future development. <i>Expert Review of Ophthalmology</i> , 2008, 3, 85-96.	0.3	0
242	Ophthalmic manifestations and risk factors for mortality of HIV patients in the post-highly active anti-retroviral therapy era: response. <i>Clinical and Experimental Ophthalmology</i> , 2011, 39, 919-919.	1.3	0
243	Letter to the Editor Regarding “The Endophthalmitis Kit”. <i>Asia-Pacific Journal of Ophthalmology</i> , 2014, 3, 130.	1.3	0
244	The Rate of Endophthalmitis After Intravitreal Injections. <i>Asia-Pacific Journal of Ophthalmology</i> , 2016, 5, 165-166.	1.3	0
245	Reply. <i>Ophthalmology</i> , 2017, 124, e29-e30.	2.5	0
246	Reply. <i>Ophthalmology</i> , 2019, 126, e45-e46.	2.5	0
247	Asian perspective of eye diseases. <i>Eye</i> , 2019, 33, 1-2.	1.1	0
248	Reply. <i>Ophthalmology</i> , 2019, 126, e43-e44.	2.5	0
249	Impact of the LEAVO Study in Asia. <i>Eye</i> , 2020, 34, 211-212.	1.1	0
250	Re: Chloroquine (CQ) and Hydroxychloroquine (HQ) Retinal Toxicity Consideration in the Treatment of the Coronavirus Disease 2019 (COVID-19). <i>Asia-Pacific Journal of Ophthalmology</i> , 2020, 9, 375-376.	1.3	0
251	Reply. <i>Ophthalmology Retina</i> , 2021, 5, e41-e42.	1.2	0
252	Reply. <i>Retina</i> , 2021, 41, e56-e58.	1.0	0

#	ARTICLE	IF	CITATIONS
253	Polypoidal Choroidal Vasculopathy. Retina Atlas, 2020, , 29-37.	0.0	0